Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 25;10(11):1794.
doi: 10.3390/vaccines10111794.

An Overview of Rift Valley Fever Vaccine Development Strategies

Paul Kato Kitandwe  1 , Paul F McKay  2 , Pontiano Kaleebu  1 , Robin J Shattock  2
Affiliations
Review

An Overview of Rift Valley Fever Vaccine Development Strategies

Paul Kato Kitandwe et al. Vaccines (Basel). .

Abstract

Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that causes high fetal and neonatal mortality in ruminants and a mild to fatal hemorrhagic fever in humans. There are no licensed RVF vaccines for human use while for livestock, commercially available vaccines are all either live attenuated or inactivated and have undesirable characteristics. The live attenuated RVF vaccines are associated with teratogenicity and residual virulence in ruminants while the inactivated ones require multiple immunisations to induce and maintain protective immunity. Additionally, nearly all licensed RVF vaccines lack the differentiating infected from vaccinated animals (DIVA) property making them inappropriate for use in RVF nonendemic countries. To address these limitations, novel DIVA-compatible RVF vaccines with better safety and efficacy than the licensed ones are being developed, aided fundamentally by a better understanding of the molecular biology of the RVF virus and advancements in recombinant DNA technology. For some of these candidate RVF vaccines, sterilizing immunity has been demonstrated in the discovery/feasibility phase with minimal adverse effects. This review highlights the progress made to date in RVF vaccine research and development and discusses the outstanding research gaps.

Keywords: RVF; RVFV; Rift Valley fever vaccine; Rift Valley fever virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure and genomic organization of Rift Valley fever virus. Created with Biorender.com.
See this image and copyright information in PMC

References

    1. Daubney R., Hudson J., Garnham P. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J. Pathol. Bacteriol. 1931;34:545–579. doi: 10.1002/path.1700340418. - DOI
    1. Wright D., Kortekaas J., Bowden T.A., Warimwe G.M. Rift Valley fever: Biology and epidemiology. J. Gen. Virol. 2019;100:1187–1199. doi: 10.1099/jgv.0.001296. - DOI - PMC - PubMed
    1. Adam I., Karsany M.S. Case report: Rift Valley fever with vertical transmission in a pregnant Sudanese woman. J. Med. Virol. 2008;80:929. doi: 10.1002/jmv.21132. - DOI - PubMed
    1. Wichgers Schreur P.J., Van Keulen L., Kant J., Oreshkova N., Moormann R.J., Kortekaas J. Co-housing of Rift Valley fever virus infected lambs with immunocompetent or immunosuppressed lambs does not result in virus transmission. Front. Microbiol. 2016;7:287. doi: 10.3389/fmicb.2016.00287. - DOI - PMC - PubMed
    1. Rostal M.K., Evans A.L., Sang R., Gikundi S., Wakhule L., Munyua P., Macharia J., Feikin D.R., Breiman R.F., Njenga M.K. Identification of potential vectors of and detection of antibodies against Rift Valley fever virus in livestock during interepizootic periods. Am. J. Vet. Res. 2010;71:522–526. doi: 10.2460/ajvr.71.5.522. - DOI - PubMed

LinkOut - more resources